Key result
Receipt of optimal guideline-indicated care for acute myocardial infarction improved survival for patients without comorbidities but showed no benefit for those with heart failure or stroke.
Why the study?
Comorbidity negatively impacts acute myocardial infarction prognosis, but the extent to which comorbidities influence guideline-indicated treatment provision and efficacy was unknown.
Does receipt of optimal guideline-indicated care for AMI improve long-term survival across different comorbidity states?
Cohort (n=693,388)
Yes
Does receipt of optimal guideline-indicated care for AMI improve long-term survival across different comorbidity states?
Guideline-indicated care for AMI improves survival in most patients, but its benefit is attenuated or absent in those with pre-existing heart failure or cerebrovascular disease.
Answers are grounded in this paper and cite their sources.
Optimal care was associated with AMI survival benefit except in heart failure or cerebrovascular disease; leaves open need for targeted strategies in these subgroups.
BACKGROUND: Comorbidity is common and has a substantial negative impact on the prognosis of patients with acute myocardial infarction (AMI). Whilst receipt of guideline-indicated treatment for AMI is associated with improved prognosis, the extent to which comorbidities influence treatment provision its efficacy is unknown. Therefore, we investigated the association between treatment provision for AMI and survival for seven common comorbidities. METHODS: We used data of 693,388 AMI patients recorded in the Myocardial Ischaemia National Audit Project (MINAP), 2003-2013. We investigated the association between comorbidities and receipt of optimal care for AMI (receipt of all eligible guideline-indicated treatments), and the effect of receipt of optimal care for comorbid AMI patients on long-term survival using flexible parametric survival models. RESULTS: A total of 412,809 [59.5%] patients with AMI had at least one comorbidity, including hypertension (302,388 [48.7%]), diabetes (122,228 [19.4%]), chronic obstructive pulmonary disease (COPD, 89,221 [14.9%]), cerebrovascular disease (51,883 [8.6%]), chronic heart failure (33,813 [5.6%]), chronic renal failure (31,029 [5.0%]) and peripheral vascular disease (27,627 [4.6%]). Receipt of optimal care was associated with greatest survival benefit for patients without comorbidities (HR 0.53, 95% CI 0.51-0.56) followed by patients with hypertension (HR 0.60, 95% CI 0.58-0.62), diabetes (HR 0.83, 95% CI 0.80-0.87), peripheral vascular disease (HR 0.85, 95% CI 0.79-0.91), renal failure (HR 0.89, 95% CI 0.84-0.94) and COPD (HR 0.90, 95% CI 0.87-0.94). For patients with heart failure and cerebrovascular disease, optimal care for AMI was not associated with improved survival. CONCLUSIONS: Overall, guideline-indicated care was associated with improved long-term survival. However, this was not the case in AMI patients with concomitant heart failure or cerebrovascular disease. There is therefore a need for novel treatments to improve outcomes for AMI patients with pre-existing heart failure or cerebrovascular disease.
No takes yet. Share an insight, caveat, or question.
Yadegarfar et al. (2020) conducted a cohort in Acute myocardial infarction (n=693,388). Receipt of optimal guideline-indicated care for AMI vs. Suboptimal care was evaluated on Long-term survival (all-cause mortality) (HR 0.53, 95% CI 0.51-0.56). Receipt of optimal guideline-indicated care for acute myocardial infarction improved survival for patients without comorbidities but showed no benefit for those with heart failure or stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: